Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

for
Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Location: Danbury CT, Bensalem PA, Morgantown WV, Waukesha WI,
Sponsor: Genmab

Sex: Female

Age: 18+

Code: NCT07564141

Phase 3, Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

for
Ovarian Neoplasms
Location: Montreal, Toronto
Sponsor: GlaxoSmithKline

Sex: Female

Age: 18+

Code: NCT07286266

Phase 3, Recruiting

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

for
Platinum-resistant Ovarian Cancer
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT07489287

Phase 1, Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, New York NY, Camden NJ,
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT07059845

Phase 2, Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

for
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer,
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT05000294

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

for
Ovarian Cancer
Location: Philadelphia PA, Baltimore MD, Orlando FL,
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT07546500

Phase 3, Recruiting

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

for
Breast Cancer, Ovarian Cancer
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 25+

Code: NCT06760507

Recruiting

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

for
Ovarian Cancer
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: Female

Age: 21+

Code: NCT06665945

Recruiting

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

for
Esophageal Squamous Cell Carcinoma,
Location: New Haven CT, Lake Success NY, New York NY,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07503808

Phase 1, Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

for
Ovarian Neoplasms, Ovarian Cancer
Location: Scarborough ME, Providence RI, Chicoutimi, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07318558

Phase 3, Recruiting

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

for
Hepatopancreaticobiliary (HPB) Malignancy,
Location: Houston TX
Sponsor: The Methodist Hospital Research Institute

Sex: All

Age: 18+

Code: NCT07050771

Phase 2, Recruiting

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

for
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: Female

Age: 18+

Code: NCT07144826

Early Phase 1, Recruiting

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

for
Ovarian Carcinoma, Psychiatric Disorder
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07282158

Recruiting

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

for
Ovarian Cancer
Location: Houston TX
Sponsor: Theolytics Limited

Sex: Female

Age: 18+

Code: NCT07211659

Phase 1, Recruiting

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

for
Ovarian Cancer,
Location: Duarte CA
Sponsor: PhotonPharma, Inc.

Sex: Female

Age: 18+

Code: NCT06366490

Phase 1, Recruiting

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

for
Ovarian Cancer
Location: Manchester NH, Lebanon NH
Sponsor: Tyler J Curiel

Sex: Female

Age: 18+

Code: NCT06815497

Phase 2, Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

for
Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer,
Location: Austin TX
Sponsor: Natera, Inc.

Sex: All

Age: 18+

Code: NCT07318051

Recruiting

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

for
FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers,
Location: New York NY, Durham NC, Rochester MN, Irvine CA,
Sponsor: TORL Biotherapeutics, LLC

Sex: Female

Age: 18 - 70+

Code: NCT07322094

Phase 1, Phase 2, Recruiting

EHR Intervention to Increase HBOC Genetic Testing

for
Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Location: New York NY
Sponsor: Columbia University

Sex: Female

Age: 21 - 70+

Code: NCT07876349

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Scarborough ME, Providence RI, Farmington CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213804

Phase 3, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial